http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201201616-A1
Outgoing Links
Predicate | Object |
---|---|
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00 |
filingDate | 2012-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2014-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EA-201201616-A1 |
titleOfInvention | ANTI-TUMOR MEDICINE (OPTIONS) |
abstract | The invention relates to the pharmaceutical industry and medicine and can be used in the creation and application of anticancer drugs, in particular bortezomiba-based proteasome inhibitors. The present invention is the creation of an effective anticancer agent on the basis of bortezomib with enhanced properties during use. The problem is solved due to the fact that the anticancer agent contains bortezomib, mineral substances, carbon isotopes, nitrogen isotopesN. Technical results of the invention are to increase the therapeutic effect without increasing the concentration of bortezomib in the treatment of malignant tumors due to the use in the antitumor agent isotopes C, N and minerals; increase storage time, including in ready-to-use liquid form. |
priorityDate | 2012-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.